Cancer Ablation by Water Vapor
Effective Gentle Treatment
water vapor technology
Convective water vapor energy technology is a platform to treat a variety of endourological conditions beginning with BPH, which was cleared by FDA in 2015 and launched soon thereafter as the Rezūm® System. The technology applies the thermal energy stored in sterile water vapor to convectively deliver targeted, precise treatments to the cancerous prostate tissue in a simple transurethral procedure. Clinical studies of twenty nine in-vivo patients, which have been treated outside the U.S., have provided data that is significantly better than other minimally invasive therapies which have been in use for over a decade.
This completely new treatment for prostate cancer is bold in concept, but gentle to the patient. Following the treatment, patients go home and most are back to their regular lifestyle the next day versus traditional prostate cancer treatment which entails surgical treatment, hospital stay and devastating side effects including incontinence and sexual dysfunction.
water vapor technology
Convective water vapor energy technology is a platform to treat a variety of endourological conditions beginning with BPH, which was cleared by FDA in 2015 and launched soon thereafter as the Rezum® System. The technology applies the thermal energy stored in sterile water vapor to convectively deliver targeted, precise treatments to the cancerous prostate tissue in a simple transurethral procedure. This completely new treatment for prostate cancer is bold in concept, but gentle to the patient.
Types of Cancer
Prostate cancer is one of the most common cancers incurred by men in the United States (US) and is a majorpublic health issue. In 2018 there will be an estimated 164,690 new cases, and 29,430 deaths attributed to prostate cancer in the US1. In approximately 90 percent of men with prostate cancer, the disease is considered to be confined to the prostate gland (clinically localized disease). The incidence of reported prostate cancer has increased with the introduction of the prostate-specific antigen (PSA) blood test. Although the disease-specific mortality rates continue to decline, prostate is the second leading cause of cancer death in men, and currently there are nearly 2.9 million American men living with the disease2. Half of the US men diagnosed annually with localized prostate cancer meet the American Urological Association’s (AUA’s) “low risk” criteria3 based on
Gleason score and PSA values.
Prostate cancer is primarily found in the peripheral zone (>70% of the time) and sometimes in the transition zone (TZ) (AUA Website). Verma et al.4 evaluated 197 tumors after radical prostatectomy and found that 65% of these tumors were found in the peripheral zone and 35% of these tumors were in the middle of the gland (transition zone and central zone combined). A small fraction of the prostate cancer tumors are found only in the central zone, and these tumors tend to be aggressive in nature when present.
According to the Kidney Cancer Association, about 50,000 people in the United States are diagnosed with kidney cancer each year. At least one genetic disorder, called von Hippel-Lindau disease, is associated with a high risk of kidney cancer. However, most risk factors are similar to other cancer types. These factors include
smoking and obesity.
Early detection can improve prognosis. Symptoms of kidney cancer may include blood in the urine, an abdominal mass, and back or flank pain.
Bladder cancer is the fourth most common cancer in men. It accounts for about 5 percent of all new cancer cases in the United States. As with most types of cancer, the risk of bladder cancer increases with age. Smokers are two times more likely to develop it than nonsmokers, according to the Bladder Cancer Advocacy Network (BCAN).
To show your support, you can take part in annual AmpUp! walks. They are supported by the BCAN and take place in May.